Now with Spectral Shift and TRIC, two methods for measuring molecular interactions, Dianthus delivers high-quality data, has the sensitivity to detect more true binders, and requires less assay development to give you results from real-life samples. Immobilization-dependent SPR, and sample-consuming ITC really struggle with affinity screening campaigns for applications involving PROTAC binary and ternary complexes, fragment libraries, and intrinsically disordered proteins. These are precisely the applications where Dianthus excels.
Ready to tackle your challenging affinity screening?
Discover tools you can use
See more related content
When you’re entrusted with developing therapeutics for challenging or undruggable targets, it’s a struggle to characterize molecular interactions. And it’s not for lack of effort or expertise — SPR an
Use this downloadable list of 2023 Targeted Protein Degradation conferences to choose which one(s) to attend. Learn when and where they’ll happen, who’ll be there, and the main focus.
NanoTemper Technologies, announced today the launch of Spectral Shift technology within their Dianthus instrument, built to handle the most challenging affinity-based screenings in drug discovery....
Targeted Protein Degradation (TPD), a relatively new therapeutic approach, is making waves by targeting otherwise ‘undruggable’ proteins. PROTACs are the best-understood protein degraders, with...
Watch this webinar if you’re working in the field of small molecule drug discovery and want to learn how scientists in this field use biophysical tools to search for the most promising lead compounds.
Update: See which 2023 conferences you should watch for With so much interest and investment in target protein degradation, a lot can happen in a year. Here are 9 conferences to get up-to-date on...
With PROTACs currently in the clinical and preclinical stages, they are making exciting progress towards successfully treating patients who have been waiting for effective therapies for certain...
Targeted protein degradation using molecular glues or proteolysis-targeting chimeras (PROTACs) is an increasingly important therapeutic modality, especially for undruggable targets. Even with candidat
Are you working in the field of small molecule drug discovery? Join this webinar to explore the drug discovery workflow and discover tools that can help in your quest for the most promising lead com
Bifunctional degrader molecules (aka PROTACs) and molecular glues recruit proteins to E3 ubiquitin ligases, forming a ternary complex that enables ubiquitination and degradation of the target